Increase Test Reliability • Reduce Error Variance • Ensure Data Quality
NeuroCog Trials provides rigorous scientific oversight to help improve signal detection and accelerate drug development for Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI). Services include streamlined training, certification, and data review for neurocognitive and clinical measures in global trials.
We combine methodological rigor with clinical neuroscience to ensure that the reliability and validity of measures are fully realized.
Our staff operates worldwide with experience in over 25 countries and validated support in 27 languages.
We provide comprehensive support including rater training and data review for neurocognitive endpoints in Alzheimer’s disease trials.
Preclinical AD Experience
We support traditional AD endpoints as well as custom batteries to assess cognitive decline in preclinical and prodromal MCI/AD.
In-House Developed Tools
Our Virtual Reality Functional Capacity Assessment Tool places patients in everyday situations through a computerized interface. VRFCAT testing eases administrator burden and automatizes transfer of data for storage.
For more information about VRFCAT, navigate here.
Also developed by NeuroCog Trials is the Brief Assessment of Cognition. BAC is a six-test battery of quick and efficient assessments, sensitive to cognitive impairment in a variety of patient populations. It comes as a paper-en-pen variant as well as a tablet version, which is now available on iTunes.
For more information about BAC, navigate here.
AD & MCI Related Publications
Impact of Expert Data Review and Centralized Scoring on Test-Retest Reliability of the ADAS-Cog
Cultural Adaptation of Translated Neurocognitive Assessments in Russia, Switzerland and Italy: Pilot Testing for a Program to Delay the Onset of Mild Cognitive Impairment due to Alzheimer’s Disease
Assessment of age-related differences in functional capacity using the Virtual Reality Functional Assessment Tool (VRFCAT)
NeuroCog Trials Receives $1.4MM Grant From The National Institute On Aging
Scientific Advisory Board
Lon Schneider, M.D. Professor of Psychiatry, Neurology and Gerontology, Keck School of Medicine at the University of Southern California
Rachelle Doody, M.D., Ph.D. Professor of Neurology, Baylor College of Medicine
Terry Goldberg, Ph.D. Director of Research in Neurocognition, Litwin-Zucker Alzheimer’s Disease Center at the Albert Einstein College of Medicine
Kathleen Welsh-Bohmer, Ph.D. Professor of Psychiatry and Director of the Bryan Alzheimer's Disease Research Center, Duke University Medical Center
John Harrison, Ph.D. Honorary Senior Lecturer in the Dept. of Medicine, Imperial College London; Principal Consultant, Metis Cognition Ltd.
Mary Sano, Ph.D. Professor of Psychiatry and Director of the Alzheimer's Disease Research, Mount Sinai School of Medicine; Director of Research and Development, Bronx Veterans Administration Hospital